Today, we list 3 biopharma companies that have FDA events approaching along with positive analyst sentiment. In other words, analysts expect these companies’ …
This market-beating fund manager is slashing ACRX and SGYP, but upping ATRS.
The complete response letter: Antares and AcelRx have just gotten the kind of mail no one wants to receive.